Pasithea Therapeutics (KTTA) announced the appointment of Dr. James Lee to its scientific advisory board, SAB, to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease, IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study
- Pasithea Therapeutics announces preclinical data on PAS-004
- Pasithea Therapeutics announces initiation of Phase 1/1b study of PAS-004
- 3 Penny Stocks to Watch Now, 5/8/25
- Pasithea Therapeutics Raises $6.3 Million in Stock Offering